Loomis Sayles & Co. L P Trims Position in CRISPR Therapeutics AG (NASDAQ:CRSP)

Loomis Sayles & Co. L P decreased its holdings in shares of CRISPR Therapeutics AG (NASDAQ:CRSP - Free Report) by 6.1% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 945,267 shares of the company's stock after selling 60,946 shares during the quarter. Loomis Sayles & Co. L P owned about 1.11% of CRISPR Therapeutics worth $44,408,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also recently made changes to their positions in the stock. Global Trust Asset Management LLC grew its stake in CRISPR Therapeutics by 150.0% during the second quarter. Global Trust Asset Management LLC now owns 500 shares of the company's stock valued at $27,000 after acquiring an additional 300 shares in the last quarter. Larson Financial Group LLC increased its holdings in shares of CRISPR Therapeutics by 95.5% in the second quarter. Larson Financial Group LLC now owns 565 shares of the company's stock worth $31,000 after purchasing an additional 276 shares during the period. GPS Wealth Strategies Group LLC boosted its stake in CRISPR Therapeutics by 99.7% during the second quarter. GPS Wealth Strategies Group LLC now owns 615 shares of the company's stock valued at $33,000 after buying an additional 307 shares during the period. Itau Unibanco Holding S.A. purchased a new position in CRISPR Therapeutics during the second quarter worth about $35,000. Finally, Darwin Wealth Management LLC bought a new position in CRISPR Therapeutics in the 3rd quarter worth about $43,000. Hedge funds and other institutional investors own 69.20% of the company's stock.

CRISPR Therapeutics Stock Performance

Shares of CRSP traded down $1.09 on Tuesday, reaching $49.31. The stock had a trading volume of 1,189,457 shares, compared to its average volume of 1,490,032. The firm has a market capitalization of $4.21 billion, a price-to-earnings ratio of -17.81 and a beta of 1.67. The company has a 50-day simple moving average of $48.03 and a 200-day simple moving average of $51.70. CRISPR Therapeutics AG has a 12-month low of $43.42 and a 12-month high of $91.10.

CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last posted its quarterly earnings data on Tuesday, November 5th. The company reported ($1.01) EPS for the quarter, topping the consensus estimate of ($1.42) by $0.41. CRISPR Therapeutics had a negative net margin of 118.13% and a negative return on equity of 12.15%. The business had revenue of $0.60 million for the quarter, compared to analyst estimates of $6.65 million. During the same quarter in the previous year, the firm posted ($1.41) earnings per share. On average, analysts expect that CRISPR Therapeutics AG will post -5.2 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, CEO Samarth Kulkarni sold 30,000 shares of the firm's stock in a transaction that occurred on Monday, November 11th. The shares were sold at an average price of $55.62, for a total transaction of $1,668,600.00. Following the completion of the sale, the chief executive officer now owns 196,540 shares of the company's stock, valued at $10,931,554.80. This trade represents a 13.24 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, General Counsel James R. Kasinger sold 1,089 shares of the company's stock in a transaction that occurred on Monday, October 14th. The shares were sold at an average price of $46.28, for a total value of $50,398.92. Following the completion of the transaction, the general counsel now directly owns 62,597 shares in the company, valued at $2,896,989.16. This trade represents a 1.71 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders have sold 35,382 shares of company stock valued at $1,917,679. 4.10% of the stock is currently owned by corporate insiders.

Analyst Ratings Changes

Several research analysts have recently commented on the company. Needham & Company LLC reissued a "buy" rating and set a $84.00 price objective on shares of CRISPR Therapeutics in a report on Wednesday, November 6th. StockNews.com raised shares of CRISPR Therapeutics to a "sell" rating in a research note on Thursday, November 7th. Barclays lowered their price objective on shares of CRISPR Therapeutics from $59.00 to $55.00 and set an "equal weight" rating on the stock in a research report on Wednesday, November 6th. Stifel Nicolaus reduced their target price on CRISPR Therapeutics from $60.00 to $59.00 and set a "hold" rating on the stock in a research note on Tuesday, August 6th. Finally, Royal Bank of Canada reaffirmed a "sector perform" rating and set a $53.00 price target on shares of CRISPR Therapeutics in a research note on Wednesday, November 6th. Three investment analysts have rated the stock with a sell rating, eight have issued a hold rating and nine have given a buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Hold" and an average target price of $74.94.

CRISPR Therapeutics Profile

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.